BICYCLE THERAPEUTICS
LIVE

Serial Number

79351833

Owner

Bicycletx Limited

Attorney

Christina M. Licursi

Filing Date

Nov 26, 2021

Add to watchlist:

No watchlists yet
View on USPTO

BICYCLE THERAPEUTICS Trademark

Serial Number: 79351833 • Registration: 7178565

BICYCLE THERAPEUTICS is a trademark filed by Bicycletx Limited on November 26, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Bicycletx Limited (33 trademarks)

Blocks A & B Portway Building,

Entity Type: 99

Trademark Details

Filing Date

November 26, 2021

Registration Date

October 3, 2023

Published for Opposition

July 18, 2023

Goods & Services

Pharmaceuticals, namely, preparations and products for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for use in the treatment and prevention of metabolic disease, urology and renal disease, in the cardiovascular field, in the field of hematology, for use in the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevetion of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease

Medical services; healthcare services for the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for the treatment and prevention of metabolic disease, urology and renal disease, cardiovascular diseases, for the treatment and prevention of disease in the field of hematology, for the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; medical and pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in the field of respiratory disease; medical services in the field of cardiovascular disease; medical services in the field of metabolic disease; medical services in the field of the treatment and/or prevention of viral infections; medical services in the field of diagnostics and imaging; medical services in the field of renal disease; medical services in the field of gastrointestinal disease; medical services in the field of muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid; medical testing for diagnostic or treatment purposes in the field of oncology for both solid and liquid tumours, metabolic disease, urology and renal disease, cardiovascular diseases, hematology, respiratory disease, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders

Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 26, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 26, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 26, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 26, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 26, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 26, 2025 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 30, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jan 9, 2024 FICS
FINAL DISPOSITION PROCESSED
Jan 9, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 3, 2024 FICR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Dec 16, 2023 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Dec 1, 2023 NREP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 3, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 3, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 18, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jul 18, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 28, 2023 NONP
EXAMINERS AMENDMENT MAILED
Jun 13, 2023 CNEA
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 13, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 13, 2023 XAEC
EXAMINERS AMENDMENT -WRITTEN
Jun 13, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 12, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 12, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 12, 2023 TROA
REFUSAL PROCESSED BY IB
Jan 15, 2023 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 23, 2022 RFCS
REFUSAL PROCESSED BY MPU
Dec 22, 2022 RFRR
APPLICATION FILING RECEIPT MAILED
Oct 11, 2022 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 8, 2022 RFCR
NON-FINAL ACTION WRITTEN
Oct 7, 2022 CNRT
ASSIGNED TO EXAMINER
Oct 7, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 7, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 6, 2022 REPR